BlackRock’s 11.3% Stake Sparks 16.6% Rally in Inspire Medical After Q3 Filing
By ATTN Desk · Editorial oversight: Sean Han
Company Overview
Inspire Medical Systems, Inc (ticker: INSP) is a public medical technology company listed on the New York Stock Exchange. Headquartered in Golden Valley, Minnesota, and founded in 2007 as a spin-out from Medtronic, Inspire develops implantable neurostimulation therapies for patients with moderate to severe obstructive sleep apnea (OSA). Its Inspire® system—comprising an implant, remote control, and mobile app—is the first FDA-approved device of its kind, providing a mask-free alternative for OSA treatment.
Corporate Structure
As of 2025, Inspire employs between 1,001 and 5,000 professionals across research and development, manufacturing, clinical affairs, and corporate functions. The company collaborates with sleep medicine specialists and ENT surgeons nationwide to train providers and support patient care. Inspire’s governance structure includes a board of directors and an executive leadership team responsible for strategy, regulatory compliance, and financial oversight.
Neurostimulation by David Matos
Recent Developments
- On October 17, 2025, Inspire amended its Schedule 13G to report that BlackRock, Inc. holds 3,353,407 shares—11.3% of outstanding common stock—with sole voting power over 3,283,122 shares.
- On November 3, 2025, Inspire filed its Form 10-Q for the quarter ended September 30, 2025, followed by a Form 8-K disclosing third-quarter operating results (Items 2.02, 7.01, and 9.01).
- On November 4, 2025, INSP shares closed at $85.9450, reflecting a 16.60% increase on a volume of 605,561.
Financial and Strategic Analysis
Inspire’s market capitalization stood at approximately $2.18 billion as of November 4, 2025. Selected trailing twelve-month (TTM) metrics from Yahoo Finance are shown below:
| Metric | Value |
|---|---|
| Price/Earnings (TTM) | 42.36 |
| Earnings Per Share (TTM) | $1.74 |
| Revenue (TTM) | $861.31 M |
| Net Income (TTM) | $53.12 M |
| Profit Margin | 6.17% |
| Return on Assets (TTM) | 3.38% |
| Return on Equity (TTM) | 8.07% |
| Total Cash (MRQ) | $300.9 M |
| Total Debt/Equity (MRQ) | 4.88% |
| Free Cash Flow (TTM) | $55.1 M |
Analysts have assigned a Sell rating, with price targets ranging from $61.00 to $66.00 and a 12-month estimate of $117.40. Subratings include Low for management and financial strength, Medium for safety and value, and Low for growth prospects.
Market Position and Industry Context
Inspire operates in the medical equipment manufacturing industry, specializing in fully implantable neurostimulation devices for OSA. Its therapy stimulates key airway muscles in sync with a patient’s breathing, providing an option to continuous positive airway pressure (CPAP). The company maintains an Inspire-trained provider network, conducts educational events, and reports patient outcomes—such as satisfaction rates and reduction in apnea events—to distinguish its offerings in a competitive OSA treatment market.
tl;dr
On November 3, 2025, Inspire Medical Systems filed its Q3 2025 10-Q and an 8-K with operating results. The previous day, an amended Schedule 13G revealed BlackRock’s 11.3% stake. On November 4, the stock increased by 16.60% to $85.9450. With a market cap near $2.2 billion, TTM revenue of $861 million, and a P/E of 42.36, INSP carries a Sell consensus and 12-month price targets between $61.00 and $117.40.